Phase II study of the combination Bendamustine and sc Alemtuzumab for patients with refractory or relapsed B-cell chronic lynphocytic leukaemia.
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2013
At a glance
- Drugs Alemtuzumab (Primary) ; Bendamustine (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms BEN-CAM
- 30 Nov 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 29 Jul 2011 New trial record